SCHEMBL3974900

SCHEMBL3974900

Cc1nc2ccccc2n1Cc1ccc([NH])cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 2/20 0.77
GALR3 O60755 3/20 0.75
NR2F2 P24468 3/20 0.75
RAB9A P51151 3/20 0.75
HDAC1 Q13547 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
NPC1 O15118 1/20 0.59
TP53 P04637 2/20 0.55
ALDH1A1 P00352 3/20 0.53
PDE6D O43924 1/20 0.53
ALDH2 P05091 1/20 0.53
ALDH3A1 P30838 1/20 0.53
LMNA P02545 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
HTT P42858 2/20 0.52
MEN1 O00255 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
KDM4E B2RXH2 1/20 0.51
CNR2 P34972 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6833621 0.87 TNF (0.81) TNFGALR3NR2F2RAB9AHDAC1
SCHEMBL231295 0.87 TNF (1.00) TNFGALR3NR2F2RAB9AHDAC1
Chlormidazole SCHEMBL148113 0.86 GALR3 (1.00) TNFGALR3NR2F2RAB9AHDAC1
Chlormidazole SCHEMBL30402878 0.86 GALR3 (1.00) TNFGALR3NR2F2RAB9AHDAC1
SCHEMBL8320197 0.84 TNF (0.77) TNFGALR3NR2F2RAB9AHDAC1
SCHEMBL12771519 0.84 GALR3 (1.00) TNFGALR3NR2F2RAB9AHDAC1
Chlormidazole SCHEMBL364033 0.84 GALR3 (0.97) TNFGALR3NR2F2RAB9AHDAC1
SCHEMBL8220572 0.84 TNF (0.77) TNFGALR3NR2F2RAB9AHDAC1
SCHEMBL9260111 0.84 TNF (0.77) TNFGALR3NR2F2RAB9AHDAC1
SCHEMBL3974904 0.84 TNF (0.77) TNFGALR3NR2F2RAB9AHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 TNF 1/4885GALR3 1701/4885NR2F2 4050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.